The promise of bispecific antibodies: Clinical applications and challenges
- 1 September 2021
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 99, 102240
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Boehringer Ingelheim
This publication has 138 references indexed in Scilit:
- Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyondLeukemia & Lymphoma, 2013
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchangeProceedings of the National Academy of Sciences, 2013
- Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate AntigensMolecular Cancer Therapeutics, 2012
- Strategies for extended serum half-life of protein therapeuticsCurrent Opinion in Biotechnology, 2011
- EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysisJournal of Clinical Pathology, 2011
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challengesBritish Journal of Cancer, 2007
- Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancerGynecologic Oncology, 2006